| 1 | doses | 24,189 |
| 2 | dosages | 1,866 |
| 3 | utilizers | 19 |
| 4 | b-values | 17 |
| 5 | dosings | 7 |
| 6 | 250mg/kg | 6 |
| 7 | dose-levels | 6 |
| 8 | coadsorption | 4 |
| 9 | grayscales | 4 |
| 10 | installments | 4 |
| 11 | programmability | 3 |
| 12 | thr239 | 3 |
| 13 | 3g-dose | 2 |
| 14 | arg152-alleles | 2 |
| 15 | dose/s | 2 |
| 16 | front-loading | 2 |
| 17 | gln/kg | 2 |
| 18 | illuminances | 2 |
| 19 | lysine-71 | 2 |
| 20 | proteinemia | 2 |
| 21 | r-squares | 2 |
| 22 | +19/+33 | 1 |
| 23 | 10-16weeks | 1 |
| 24 | 17α-position | 1 |
| 25 | 24-34weeks | 1 |
| 26 | 36thmonth | 1 |
| 27 | 4.5g/dl | 1 |
| 28 | 41days | 1 |
| 29 | 5'-termini | 1 |
| 30 | 6-year-counts | 1 |
| 31 | anticrossings | 1 |
| 32 | cdtivol | 1 |
| 33 | concenrations | 1 |
| 34 | consumpion | 1 |
| 35 | cytotocity | 1 |
| 36 | day5 | 1 |
| 37 | end-metabolites | 1 |
| 38 | entry/exit | 1 |
| 39 | fixed-ratios | 1 |
| 40 | gd20 | 1 |
| 41 | induction/synchronization | 1 |
| 42 | n327 | 1 |
| 43 | nucleophilicities | 1 |
| 44 | other-fold | 1 |
| 45 | paradigma | 1 |
| 46 | regenerations | 1 |
| 47 | s139 | 1 |
| 48 | ser-230 | 1 |
| 49 | ser-3 | 1 |
| 50 | than-2.4 | 1 |
| 51 | ∼24h | 1 |
| 1 | +19/+33 | 1 |
| 2 | 10-16weeks | 1 |
| 3 | 17α-position | 1 |
| 4 | 24-34weeks | 1 |
| 5 | 250mg/kg | 6 |
| 6 | 36thmonth | 1 |
| 7 | 3g-dose | 2 |
| 8 | 4.5g/dl | 1 |
| 9 | 41days | 1 |
| 10 | 5'-termini | 1 |
| 11 | 6-year-counts | 1 |
| 12 | anticrossings | 1 |
| 13 | arg152-alleles | 2 |
| 14 | b-values | 17 |
| 15 | cdtivol | 1 |
| 16 | coadsorption | 4 |
| 17 | concenrations | 1 |
| 18 | consumpion | 1 |
| 19 | cytotocity | 1 |
| 20 | day5 | 1 |
| 21 | dosages | 1,866 |
| 22 | dose-levels | 6 |
| 23 | dose/s | 2 |
| 24 | doses | 24,189 |
| 25 | dosings | 7 |
| 26 | end-metabolites | 1 |
| 27 | entry/exit | 1 |
| 28 | fixed-ratios | 1 |
| 29 | front-loading | 2 |
| 30 | gd20 | 1 |
| 31 | gln/kg | 2 |
| 32 | grayscales | 4 |
| 33 | illuminances | 2 |
| 34 | induction/synchronization | 1 |
| 35 | installments | 4 |
| 36 | lysine-71 | 2 |
| 37 | n327 | 1 |
| 38 | nucleophilicities | 1 |
| 39 | other-fold | 1 |
| 40 | paradigma | 1 |
| 41 | programmability | 3 |
| 42 | proteinemia | 2 |
| 43 | r-squares | 2 |
| 44 | regenerations | 1 |
| 45 | s139 | 1 |
| 46 | ser-230 | 1 |
| 47 | ser-3 | 1 |
| 48 | than-2.4 | 1 |
| 49 | thr239 | 3 |
| 50 | utilizers | 19 |
| 51 | ∼24h | 1 |
| 1 | gd20 | 1 |
| 2 | ser-230 | 1 |
| 3 | lysine-71 | 2 |
| 4 | ser-3 | 1 |
| 5 | +19/+33 | 1 |
| 6 | than-2.4 | 1 |
| 7 | day5 | 1 |
| 8 | n327 | 1 |
| 9 | s139 | 1 |
| 10 | thr239 | 3 |
| 11 | proteinemia | 2 |
| 12 | paradigma | 1 |
| 13 | other-fold | 1 |
| 14 | 3g-dose | 2 |
| 15 | 250mg/kg | 6 |
| 16 | gln/kg | 2 |
| 17 | front-loading | 2 |
| 18 | ∼24h | 1 |
| 19 | 36thmonth | 1 |
| 20 | 5'-termini | 1 |
| 21 | 4.5g/dl | 1 |
| 22 | cdtivol | 1 |
| 23 | consumpion | 1 |
| 24 | induction/synchronization | 1 |
| 25 | 17α-position | 1 |
| 26 | coadsorption | 4 |
| 27 | dose/s | 2 |
| 28 | illuminances | 2 |
| 29 | dosages | 1,866 |
| 30 | nucleophilicities | 1 |
| 31 | grayscales | 4 |
| 32 | arg152-alleles | 2 |
| 33 | r-squares | 2 |
| 34 | doses | 24,189 |
| 35 | end-metabolites | 1 |
| 36 | b-values | 17 |
| 37 | dosings | 7 |
| 38 | anticrossings | 1 |
| 39 | 24-34weeks | 1 |
| 40 | 10-16weeks | 1 |
| 41 | dose-levels | 6 |
| 42 | regenerations | 1 |
| 43 | concenrations | 1 |
| 44 | fixed-ratios | 1 |
| 45 | utilizers | 19 |
| 46 | installments | 4 |
| 47 | 6-year-counts | 1 |
| 48 | 41days | 1 |
| 49 | entry/exit | 1 |
| 50 | cytotocity | 1 |
| 51 | programmability | 3 |